Pulmonary complications of biological therapies in children and adults with rheumatic diseases

Paediatr Respir Rev. 2013 Dec;14(4):236-41. doi: 10.1016/j.prrv.2012.12.007. Epub 2013 Feb 23.


The management of rheumatic conditions, including those occurring in children, has improved dramatically over the last decade following the introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDS) into the therapeutic arsenal. The benefits have been realised in multiple aspects of disease including signs and symptoms, bone and cartilage destruction, disability and quality of life. Overall, bDMARDS have an acceptable safety profile in the short to medium term in adults and children, however, that following longer term use remains unclear. As these drugs target key signalling molecules and cells of the immune system, adverse events are not unanticipated. In this review we will discuss pulmonary complications of biologic therapies used in the management of rheumatic diseases in both children and adults.

Keywords: Biologics; Complications; ILD; Pulmonary; Safety; bDMARDS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Biological Factors / adverse effects*
  • Biological Factors / therapeutic use
  • Biological Therapy / adverse effects*
  • Child
  • Global Health
  • Humans
  • Immune System / drug effects*
  • Incidence
  • Lung Diseases* / chemically induced
  • Lung Diseases* / epidemiology
  • Lung Diseases* / immunology
  • Rheumatic Diseases / drug therapy*
  • Rheumatic Diseases / immunology
  • Young Adult


  • Antirheumatic Agents
  • Biological Factors